resiquimod has been researched along with loratadine in 2 studies
| Studies (resiquimod) | Trials (resiquimod) | Recent Studies (post-2010) (resiquimod) | Studies (loratadine) | Trials (loratadine) | Recent Studies (post-2010) (loratadine) |
|---|---|---|---|---|---|
| 465 | 14 | 318 | 1,317 | 462 | 339 |
| Protein | Taxonomy | resiquimod (IC50) | loratadine (IC50) |
|---|---|---|---|
| Cytochrome P450 2C19 | Homo sapiens (human) | 0.016 | |
| Histamine H1 receptor | Homo sapiens (human) | 0.23 | |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 0.245 | |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 0.1717 | |
| Bile acid receptor | Homo sapiens (human) | 3.07 | |
| Sodium-dependent neutral amino acid transporter B(0)AT2 | Homo sapiens (human) | 4 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Chen, T; Lin, G; Lin, X; Wang, X; Zhang, J | 1 |
2 other study(ies) available for resiquimod and loratadine
| Article | Year |
|---|---|
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Pre-activation with TLR7 in combination with thioridazine and loratadine promotes tumoricidal T-cell activity in colorectal cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Colorectal Neoplasms; Cytokines; Dendritic Cells; Imidazoles; Loratadine; Membrane Glycoproteins; Mice, Inbred BALB C; T-Lymphocytes, Cytotoxic; Thioridazine; Toll-Like Receptor 7 | 2020 |